Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
81
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Metsera Inc. market cap is $7.43B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Metsera Inc. 52 week high is $83.86 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Metsera Inc. 52 week low is $12.30 as of November 22, 2026.
Metsera Inc. stock price today is $70.50.
Metsera Inc. stock price yesterday was $70.75.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Metsera Inc.'s P/E ratio is -23.55.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Metsera Inc. P/B ratio is 21.9854.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Metsera Inc. 50-day moving average is $56.89.